Recombinant Human Erythropoietin Treatment for Chemotherapy-related Anemia in Children

Ali Varan, MD; Münever Büyükpamukçu, MD; Tezer Kutluk, MD, PhD; and Canan Akyüz, MD

ABSTRACT. Objective. The efficacy and safety of recombinant human erythropoietin (rHuEPO) treatment in chemotherapy-induced anemia in children was investigated. rHuEPO is used to treat chemotherapy-induced anemia. Several studies recommend 150 to 300 IU/kg rHuEPO for 2 to 8 months. There are only a few controlled trials in children and no precise data about the optimal dose and duration of rHuEPO treatment is available.

Patients and Methods. Thirty-four patients receiving chemotherapy for treatment of their solid tumors between October 1996 and June 1997 were included in this study. Patients were randomly selected for each group. The male/female ratio was 20/14, and the median age was 5 years (range, 1–16 years). They had normal hemoglobin levels at the time of diagnosis. When hemoglobin levels decreased to levels lower than 10 g/dL, rHuEPO (150 IU/kg/d, 3 times a week, subcutaneously) was given to 17 patients for 2 months. Their renal, liver, and pulmonary functions were normal. None of the patients had hematologic disease. We did not use any other drugs such as iron or granulocyte colony-stimulating factor. There were 17 patients in the control group. Fifteen patients got chemotherapy regimens including cisplatin (CDDP), but 19 were treated with regimens without CDDP. At the end of rHuEPO treatment, all patients were examined in terms of transfusion requirements and rate of change in hemoglobin levels.

Results. One patient in the study group needed a blood transfusion, whereas 8 patients needed a transfusion in the control group. Patients in the study group had less transfusion requirements compared with the control group. The mean hemoglobin levels before and after the study were 8.48 ± 0.97 g/dL and 8.50 ± 1.65 g/dL in the control group and 8.68 ± 0.73 g/dL to 10.26 ± 1.84 g/dL in 9 patients treated with non-CDDP chemotherapy regimens. Mean hemoglobin level increased from 8.28 ± 0.97 g/dL to 10.15 ± 2.5 g/dL in 8 patients treated with CDDP-containing regimens in the erythropoietin group. rHuEPO caused high blood pressure in only 1 patient that resolved spontaneously after cessation of erythropoietin treatment for a week.

Conclusion. rHuEPO treatment (150 IU/kg/d 3 times a week) is effective and safe in children with chemotherapy-induced anemia. It decreases blood transfusion requirements in solid tumor patients. Our results show that the response to rHuEPO in CDDP-induced anemia is less than the response in non-CDDP receiving patients. Higher doses may be necessary in patients using CDDP.

ABBREVIATIONS. rHuEPO, recombinant human erythropoietin; CDDP, cisplatin.

Anemia in cancer patients has several causes, such as bone marrow suppression from chemotherapy, anemia of chronic disease, hemolysis, and erythropoietin deficiency because of chemotherapy-induced nephrotoxicity. Recombinant human erythropoietin (rHuEPO) is proposed to treat chemotherapy-induced anemia for reducing transfusion risks. Some authors stressed that regimens containing cisplatin (CDDP) lead to decreased erythropoietin production because of direct toxic effects on renal cells. Several studies showed efficacy of rHuEPO in these patients. Serum erythropoietin levels were found to be normal, low, or high in these studies. Different studies recommend 150 to 300 IU/kg rHuEPO for 4 to 8 months. There are only a few controlled trials in children and no precise data about the optimal dose and duration of rHuEPO treatment is available. The aim of our study is to investigate the efficacy and safety of rHuEPO in chemotherapy-induced anemia in children.

PATIENTS AND METHODS

Patients

Thirty-four patients admitted to our department between October 1996 and June 1997 were included in this study. There were 20 boys and 14 girls with a median age of 5 years (range, 1–16 years). Patients were randomly assigned to either the erythropoietin-receiving group or the control group. At the beginning of the study, an informed consent was obtained from all patients’ parents after an explanation about the study. The types of malignant diseases in patients are given in Table 1. We put the patients on different chemotherapeutic regimens including cisplatin, vincristine, cyclophosphamide, lomustine-1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, procarbazine, actinomycin D, Adriamycin, etoposide, dacarbazine, or high-dose methotrexate (in lymphoma patients) according to tumor subtype. Patients with Wilm’s tumor, Ewing’s sarcoma, rhabdomyosarcoma, or nasopharyngeal carcinoma also had local regional radiotherapy. Cranial and/or spinal
radiotherapy was applied to brain tumors according to treatment protocols. Physical examinations and blood pressure measurements were made weekly. Serum erythropoietin levels were measured at the beginning of the study in all patients and were repeated again in the rHuEPO-treated group at the end of study. Complete blood counts were performed weekly. rHuEPO was given to 17 patients for a period of 2 months. Seventeen patients were in the control group. Fifteen patients received CDDP-containing regimens and 19 patients were treated with regimens without CDDP. In the CDDP group, patients continued to have normal renal function during the treatment course.

Inclusion Criteria

The patients who fulfilled the following criteria were included in the study: a) the patients’ hemoglobin levels were >11 g/dL at the time of first admission. All patients had chemotherapy regimens because of primary malignant disease. Hemoglobin levels should be <10 g/dL at the beginning of this study. b) The hepatic, renal, and pulmonary functions were normal. c) All hematologic parameters including reticulocyte count, iron, iron-binding capacity, serum ferritin level, direct Coombs test, vitamin B12 and folate levels, and arterial pH and blood gases were normal. d) The patients who received blood transfusions during the last month before onset of rHuEPO treatment were not included.

Treatment Regimen

rHuEPO was given at a 150 IU/kg/dose, 3 times a week, subcutaneously (rHuEPO was supplied partly by Cilag Inc (Zug, Switzerland) and marketed as EPREX) in 17 patients. If a patient had any of the complications of rHuEPO treatment such as hypertension, flushing, or deep vein thrombosis, drug administration was stopped. Patients with hemoglobin levels <6 g/dL and/or symptoms of anemia were given blood transfusions. At the end of 2 months, transfusion requirements and hemoglobin measurements were compared in the study and control groups. During the treatment period we did not use any other drugs such as granulocyte colony-stimulating factor or iron that could affect the hemoglobin response.

Statistical Methods

χ² was used to compare transfusion requirements between the study group and the control group. We compared the differences of the erythropoietin and hemoglobin levels in patients treated with and without CDDP by Mann-Whitney U test. The Wilcoxon test was used to determine the significance of hemoglobin increments.

RESULTS

Chemotherapy intensities in study and control groups were compared by analyzing the absolute neutrophil and thrombocyte counts and there was no significant difference (P = .56, P = .55, respectively). At the onset of treatment, serum erythropoietin levels of all patients were found to be between 14 and 410 IU/L (median, 70 IU/L), and there was no difference between the rHuEPO group and the control group in terms of serum erythropoietin levels (P = .52; Table 2). This was also true for CDDP and non-CDDP groups (P = .14). The erythropoietin levels at the beginning were higher than the levels after erythropoietin treatment in the study group.

There was no difference in initial hemoglobin levels between rHuEPO and non-rHuEPO groups (P = .95). The difference between the Hb levels of both groups at the end of the study was statistically significant (10.21 g/dL vs 8.41 g/dL, P = .027; Table 2). The mean hemoglobin levels before and after the study were 8.48 ± 0.98 g/dL and 8.41 ± 1.65 g/dL (P = .9) in the control group. The mean hemoglobin level in the rHuEPO-treated group was 8.50 ± 0.85 g/dL before treatment and it increased to the level of 10.21 ± 2.14 g/dL (P = .0086) after rHuEPO treatment. The increase in hemoglobin levels began 4 weeks after onset of treatment and continued progressively in the rHuEPO group. Hemoglobin levels at 2, 4, 6, and 8 weeks were 8.85 ± 1.25, 9.27 ± 1.8, 9.83 ± 1.58, 10.21 ± 2.14 g/dL, respectively (Fig 1). These results were 8.71 ± 1.33, 8.62 ± 1.25, 8.99 ± 1.30, and 8.41 ± 1.65 g/dL in the control group, respectively. rHuEPO treatment was more effective in the erythropoietin group receiving the non-CDDP regimen. Mean hemoglobin level increased from 8.68 ± 0.73 g/dL to 10.26 ± 1.84 g/dL (P = .038) in 9 patients treated with the non-CDDP chemotherapy regimen, although it increased from 8.28 ± 0.97 g/dL to 10.15 ± 2.5 g/dL in 8 patients in the erythropoietin group treated with CDDP-containing regimens (P = .28; Table 3).

During the treatment period, 1 patient in the rHuEPO group and 8 patients in the control group needed blood transfusions. This is statistically signif-

<table>
<thead>
<tr>
<th>Table 2. Patient Characteristics in Study and Control Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
</tr>
<tr>
<td>Number of patients</td>
</tr>
<tr>
<td>Mean Hb level (g/dL)</td>
</tr>
<tr>
<td>At the beginning of the study</td>
</tr>
<tr>
<td>At the end of the study</td>
</tr>
<tr>
<td>P value</td>
</tr>
<tr>
<td>Median erythropoietin levels (IU/L)</td>
</tr>
<tr>
<td>At the beginning</td>
</tr>
<tr>
<td>At the end of the study</td>
</tr>
<tr>
<td>Number of transfusion requirements</td>
</tr>
</tbody>
</table>

Abbreviation: rHuEPO, recombinant human erythropoietin.
Miller and coworkers mentioned that adult patients with a Hb level lower than 9 g/dL had inadequate response to erythropoietin, and performed red cell transfusions if the Hb level returned to normal levels. rHuEPO was started again after 2 weeks of rHuEPO treatment and blood pressure during rHuEPO treatment. After cessation of the rHuEPO for 1 week, blood pressure returned to normal and we continued rHuEPO treatment without any complications. Most of the studies report few complications with this drug. Deep vein thrombosis, flushing, polycythemia, and high blood pressure are some disadvantages such as case selection bias. We observed a significant decrease in the transfusion requirement with the use of rHuEPO (8 vs 1 patient needed transfusions in the control group and the rHuEPO group, respectively). This finding suggests that rHuEPO, 150 IU/kg for 2 months, can be used effectively for treatment of chemotherapy-related anemia in children with malignancy. A good response was achieved in 4 weeks. The significant difference on the hemoglobin levels of the study and the control groups also confirmed the efficacy of rHuEPO treatment in our patients. Transfusion was done if Hb levels were lower than the 6 g/dL in our study to detect the difference between both groups. This cutoff level was relatively higher in other studies, eg, 9 g/dL in one study and 8 g/dL in another study. We believe that the higher cutoff level may shadow the real difference between the erythropoietin-treated and the erythropoietin-untreated groups. The decrease of high erythropoietin levels to normal levels in the rHuEPO-treated group also could be attributable to both normalization of Hb levels (endogenous cause) and suppression of erythropoietin synthesis by rHuEPO (exogenous cause).

Some authors reported that patients using CDDP had inadequate response to erythropoietin as a result of nephrotoxicity.

It is well-known that blood transfusions may cause many complications such as infections (HIV, hepatitis B, cytomegalovirus, etc.), iron loading, and hemolytic reactions. Use of recombinant growth factor is thought to reduce these adverse reactions by decreasing transfusion requirements. Most of the studies are related with adult cases. Firstly, Miller et al. mentioned that adult patients who had received high rHuEPO doses (100–200 IU/kg) showed a good response. Dunphy et al. reported that the rHuEPO dose should be increased in patients who used paclitaxel and carboplatin if the response was inadequate with 150 IU/kg.

There are a few studies about rHuEPO treatment in children, and the optimal dose of rHuEPO is not defined precisely. Nenadov et al. used low doses of rHuEPO for 2 weeks and did not see any response in pediatric cases. This period is very short and inadequate for evaluation of rHuEPO treatment. They used a maximum of 100 IU/kg rHuEPO, lower than other studies. Most of the studies recommend an rHuEPO treatment for 2 or 3 months in chemotherapy-induced anemia of solid tumors. Porter et al. mentioned that a starting dose of 150 IU/kg was administered to their pediatric patients with a median dose of 198 IU/kg rHuEPO per dose. They increased the rHuEPO dose if the patients had blood transusions or inadequate response. They found that a 16-week treatment with rHuEPO decreased the requirement for platelet transfusion. Our results were similar to this controlled trial for blood transfusion requirements. In our study, we used 150 IU/kg rHuEPO for 2 months without giving any iron supplement. Optimal results were obtained in 4 weeks and continued during treatment. In another study, León et al. applied 150 IU/kg rHuEPO 5 times weekly for 3 months, but they used historical controls and performed red cell transfusions if the Hb level was lower than 9 g/dL. Historical controls have some disadvantages such as case selection bias. We observed a significant decrease in the transfusion requirement with the use of rHuEPO (8 vs 1 patient needed transfusions in the control group and the rHuEPO group, respectively). This finding suggests that rHuEPO, 150 IU/kg for 2 months, can be used effectively for treatment of chemotherapy-related anemia in children with malignancy. A good response was achieved in 4 weeks. The significant difference on the hemoglobin levels of the study and the control groups also confirmed the efficacy of rHuEPO treatment in our patients. Transfusion was done if Hb levels were lower than the 6 g/dL in our study to detect the difference between both groups. This cutoff level was relatively higher in other studies, eg, 9 g/dL in one study and 8 g/dL in another study. We believe that the higher cutoff level may shadow the real difference between the erythropoietin-treated and the erythropoietin-untreated groups. The decrease of high erythropoietin levels to normal levels in the rHuEPO-treated group also could be attributable to both normalization of Hb levels (endogenous cause) and suppression of erythropoietin synthesis by rHuEPO (exogenous cause).

**DISCUSSION**

It is well-known that blood transfusions may cause many complications such as infections (HIV, hepatitis B, cytomegalovirus, etc.), iron loading, and hemolytic reactions. Use of recombinant growth factor is thought to reduce these adverse reactions by decreasing transfusion requirements. Most of the studies are related with adult cases. Firstly, Miller and coworkers mentioned that adult patients who had received high rHuEPO doses (100–200 IU/kg) showed a good response. Dunphy et al. reported that the rHuEPO dose should be increased in patients who used paclitaxel and carboplatin if the response was inadequate with 150 IU/kg.

There are a few studies about rHuEPO treatment in children, and the optimal dose of rHuEPO is not defined precisely. Nenadov et al. used low doses of rHuEPO for 2 weeks and did not see any response in pediatric cases. This period is very short and inadequate for evaluation of rHuEPO treatment. They used a maximum of 100 IU/kg rHuEPO, lower than other studies. Most of the studies recommend an rHuEPO treatment for 2 or 3 months in chemotherapy-induced anemia of solid tumors. Porter et al. mentioned that a starting dose of 150 IU/kg was administered to their pediatric patients with a median dose of 198 IU/kg rHuEPO per dose. They increased the rHuEPO dose if the patients had blood transfusions or inadequate response. They found that a 16-week treatment with rHuEPO decreased the requirement for platelet transfusion. Our results were similar to this controlled trial for blood transfusion requirements. In our study, we used 150 IU/kg rHuEPO for 2 months without giving any iron supplement. Optimal results were obtained in 4 weeks and continued during treatment. In another study, León et al. applied 150 IU/kg rHuEPO 5 times weekly for 3 months, but they used historical controls and performed red cell transfusions if the Hb level was lower than 9 g/dL. Historical controls have some disadvantages such as case selection bias. We observed a significant decrease in the transfusion requirement with the use of rHuEPO (8 vs 1 patient needed transfusions in the control group and the rHuEPO group, respectively). This finding suggests that rHuEPO, 150 IU/kg for 2 months, can be used effectively for treatment of chemotherapy-related anemia in children with malignancy. A good response was achieved in 4 weeks. The significant difference on the hemoglobin levels of the study and the control groups also confirmed the efficacy of rHuEPO treatment in our patients. Transfusion was done if Hb levels were lower than the 6 g/dL in our study to detect the difference between both groups. This cutoff level was relatively higher in other studies, eg, 9 g/dL in one study and 8 g/dL in another study. We believe that the higher cutoff level may shadow the real difference between the erythropoietin-treated and the erythropoietin-untreated groups. The decrease of high erythropoietin levels to normal levels in the rHuEPO-treated group also could be attributable to both normalization of Hb levels (endogenous cause) and suppression of erythropoietin synthesis by rHuEPO (exogenous cause).

Some authors reported that patients using CDDP had inadequate response to erythropoietin as a result of nephrotoxicity. Although there is no significant difference on erythropoietin levels of patients treated with and without CDDP-containing regimens, response to rHuEPO was better in patients treated with non-CDDP-containing regimens. Miller et al. investigated whether rHuEPO affected CDDP-induced anemia or not. They found out that rHuEPO, 100 to 200 IU/kg, were useful in those cases, but their study was only a single arm, dose escalation phase I-II study. In Cascinu’s study, 100 patients who received cisplatin were randomly assigned to either erythropoietin or nonerythropoietin groups. They compared rHuEPO and placebo, but their study did not include patients who had a non-CDDP-containing regimen. In our study, the Wilcoxon P values for hemoglobin increments of CDDP and non-CDDP groups in the erythropoietin group were .12 and .038, respectively. This difference may be decreased by giving higher rHuEPO doses. Bone marrow may not respond adequately because of the myelosuppressive effect of CDDP. The anemia of our patients improved after rHuEPO treatment. We suggest that patients using CDDP should be treated with higher dosages of rHuEPO when needed. The number of patients in the CDDP group is relatively less and further studies with a greater number of patients and different erythropoietin doses should be done.

We observed that 1 patient transiently had high blood pressure during rHuEPO treatment. After cessation of the rHuEPO for 1 week, blood pressure returned to normal and we continued rHuEPO treatment without any complications. Most of the studies report few complications with this drug. Deep vein thrombosis, flushing, polycythemia, and high blood pressure are among the reported complications. We did not observe any of these complications.

We conclude that rHuEPO treatment is effective and safe in minimizing transfusion requirements in
children with solid tumors at doses of 150 IU/kg given three times a week for 2 months. Higher doses may be necessary in patients using CDDP. Because chemotherapy-induced anemia is related to inadequate response to high endogenous erythropoietin, cancer patients may benefit from exogenous rHuEPO during chemotherapy.

REFERENCES

Recombinant Human Erythropoietin Treatment for Chemotherapy-related Anemia in Children
Ali Varan, Münevver Büyükpamukçu, Tezer Kutluk and Canan Akyüz

Pediatrics 1999;103:e16
DOI: 10.1542/peds.103.2.e16

Updated Information & Services
including high resolution figures, can be found at:
/content/103/2/e16.full.html

References
This article cites 14 articles, 3 of which can be accessed free at:
/content/103/2/e16.full.html#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
/content/103/2/e16.full.html#related-urls

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Hematology/Oncology
/cgi/collection/hematology/oncology_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 1999 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
Recombinant Human Erythropoietin Treatment for Chemotherapy-related Anemia in Children
Ali Varan, Münevver Büyükpamukçu, Tezer Kutluk and Canan Akyüz

Pediatrics 1999;103;e16
DOI: 10.1542/peds.103.2.e16

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/103/2/e16.full.html